Anti-angiogenic therapy for ovarian cancer

European Journal of Cancer, Supplement · Published 2020-08-01 · DOI 10.1016/j.ejcsup.2020.02.003

Authors being retrieved — see the publisher record. https://doi.org/10.1016/j.ejcsup.2020.02.003

Abstract

Angiogenesis is a known hallmark in cancer and plays a crucial role in ovarian cancer carcinogenesis and invasion. Anti- angiogenic agents are active in ovarian cancer treatment either as monotherapy or combined with chemotherapy, immunotherapy or poly ADP ribose polymerase (PARP) inhibitors. We review the mechanism of action, clinical activity and safety profile of the most important drugs either in the actual treatment or in current evaluation in the ovarian cancer treatment scenario (neoadjuvant, first line and relapse).

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2020

Related articles